26 related articles for article (PubMed ID: 1730894)
1. Deciphering longitudinal optical-density measurements to guide clinical dosing regimen design: A model-based approach.
Kesisoglou I; Eales BM; Merlau PR; Tam VH; Nikolaou M
Comput Methods Programs Biomed; 2022 Dec; 227():107212. PubMed ID: 36335752
[TBL] [Abstract][Full Text] [Related]
2. Bactericidal efficiency of micro- and nanostructured surfaces: a critical perspective.
Senevirathne SWMAI; Hasan J; Mathew A; Woodruff M; Yarlagadda PKDV
RSC Adv; 2021 Jan; 11(3):1883-1900. PubMed ID: 35424086
[TBL] [Abstract][Full Text] [Related]
3. Is Acrylamide as Harmful as We Think? A New Look at the Impact of Acrylamide on the Viability of Beneficial Intestinal Bacteria of the Genus
Petka K; Tarko T; Duda-Chodak A
Nutrients; 2020 Apr; 12(4):. PubMed ID: 32326187
[TBL] [Abstract][Full Text] [Related]
4. Amikacin Pharmacokinetic-Pharmacodynamic Analysis in Pediatric Cancer Patients.
Alhadab AA; Ahmed MA; Brundage RC
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358293
[TBL] [Abstract][Full Text] [Related]
5. Anti-cariogenic effect of a cetylpyridinium chloride-containing nanoemulsion.
Lee VA; Karthikeyan R; Rawls HR; Amaechi BT
J Dent; 2010 Sep; 38(9):742-9. PubMed ID: 20600554
[TBL] [Abstract][Full Text] [Related]
6. Impact of bacterial biofilm formation on in vitro and in vivo activities of antibiotics.
Schwank S; Rajacic Z; Zimmerli W; Blaser J
Antimicrob Agents Chemother; 1998 Apr; 42(4):895-8. PubMed ID: 9559803
[TBL] [Abstract][Full Text] [Related]
7. Rationale behind high-dose amoxicillin therapy for acute otitis media due to penicillin-nonsusceptible pneumococci: support from in vitro pharmacodynamic studies.
Lister PD; Pong A; Chartrand SA; Sanders CC
Antimicrob Agents Chemother; 1997 Sep; 41(9):1926-32. PubMed ID: 9303386
[TBL] [Abstract][Full Text] [Related]
8. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.
den Hollander JG; Horrevorts AM; van Goor ML; Verbrugh HA; Mouton JW
Antimicrob Agents Chemother; 1997 Jan; 41(1):95-100. PubMed ID: 8980762
[TBL] [Abstract][Full Text] [Related]
9. Once-versus thrice-daily netilmicin combined with amoxicillin, penicillin, or vancomycin against Enterococcus faecalis in a pharmacodynamic in vitro model.
Schwank S; Blaser J
Antimicrob Agents Chemother; 1996 Oct; 40(10):2258-61. PubMed ID: 8891125
[TBL] [Abstract][Full Text] [Related]
10. Once-daily dosing of aminoglycosides.
Blaser J; König C
Eur J Clin Microbiol Infect Dis; 1995 Dec; 14(12):1029-38. PubMed ID: 8681976
[TBL] [Abstract][Full Text] [Related]
11. In vivo verification of in vitro model of antibiotic treatment of device-related infection.
Blaser J; Vergères P; Widmer AF; Zimmerli W
Antimicrob Agents Chemother; 1995 May; 39(5):1134-9. PubMed ID: 7625801
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
[TBL] [Abstract][Full Text] [Related]
13. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
Robaux MA; Dube L; Caillon J; Bugnon D; Kergueris MF; Navas D; Le Conte P; Baron D; Potel G
J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
[TBL] [Abstract][Full Text] [Related]
14. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
Chan E; Zhou S; Srikumar S; Duan W
Pharm Res; 2006 Apr; 23(4):729-41. PubMed ID: 16554956
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model.
McGrath BJ; Bailey EM; Lamp KC; Rybak MJ
Antimicrob Agents Chemother; 1992 Dec; 36(12):2741-6. PubMed ID: 1482142
[TBL] [Abstract][Full Text] [Related]
16. Serum bactericidal activity of mezlocillin, ceftazidime, mezlocillin/ceftazidime and mezlocillin/amikacin against Klebsiella pneumoniae and Pseudomonas aeruginosa.
Van Laethem Y; Klastersky J
Eur J Clin Microbiol; 1986 Feb; 5(1):110-4. PubMed ID: 3084239
[TBL] [Abstract][Full Text] [Related]
17. Amikacin, ceftazidime, and flucloxacillin against suspended and adherent Pseudomonas aeruginosa and Staphylococcus epidermidis in an in vitro model of infection.
Vergères P; Blaser J
J Infect Dis; 1992 Feb; 165(2):281-9. PubMed ID: 1730894
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
